FWFiona A. Wilkes

Fiona A. Wilkes

*This is an algorithmically generated author record based on publicly available information.

Fiona A. Wilkes has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pharmacogenetics and the Blood–Brain Barrier: A Whirlwind Tour of Potential Clinical Utility

    by David R. Skvarc, Trang T. T. Truong, Robert M. Lundin, Russell Barnes, Fiona A. Wilkes, Ajeet B. Singh

    Genetic factors influence medication response (pharmacogenetics), affecting the pharmacodynamics and pharmacokinetics of many medicaments used in clinical care. The ability of medications to cross the blood–brain barrier (BBB) represents a critical putative factor in the effectiveness and tolerability of various medications relevant to central nervous system disorders (CNS), cancer, and broader medical conditions at a pharmacokinetic (dosing) level. Pharmacogenetics has the potential to personalise medicine to a greater extent than has been possible, with the potential to help reduce heuristic delays to effective tolerable pharmacotherapy. Here, we critically examine and summarise the evidence, particularly for ABCB1 polymorphisms associated with drug transportation and other clinical relevance. These transporters appear to have a role in BBB pharmacogenetics and may indicate new avenues of research that extend beyond the current paradigm of CYP450 polymorphisms. We identify some of the most promising variants for clinical translation while spotlighting the complexities of the involved systems and limitations of the current empirical literature.


  • Open Access

    Pharmacogenetics and the Blood-Brain Barrier: A Whirlwind Tour of Potential Clinical Utility

    by David Skvarc, Trang Truong, Robert Lundin, Russell Barnes, Fiona Wilkes, Ajeet Singh

    Genetic factors influence medication response (pharmacogenetics), affecting the pharmacody-namics and pharmacokinetics of many medicaments used in clinical care. The ability of medica-tions to cross the blood-brain barrier (BBB) represents a critical putative factor in the effectiveness and tolerability of various central nervous system (CNS) medications at a pharmacokinetic (dosing) level. Pharmacogenetics has the potential to personalise medicine to a greater extent than has been possible, with the potential to help reduce heuristic delays to effective tolerable pharmacotherapy. Here, we critically examine and summarise the evidence, particularly for ABCB1 polymorphisms associated with various CNS medications. These transporters appear to have a role in BBB pharmacogenetics. We identify some of the most promising variants for clinical translation while spotlighting the complexities of the involved systems and limitations of the current empirical literature.

  • Morphometric analysis of thalamic volume in progressive supranuclear palsy: In vivo evidence of regionally specific bilateral thalamic atrophy

    by Brian D. Power, David Jakabek, Mitchell Hunter-Dickson, Fiona A. Wilkes, Danielle van Westen, Alexander. F. Santillo, Mark Walterfang, Dennis Velakoulis, Christer Nilsson, Jeffrey C.L. Looi